Glunz & Jensen Holding A/S
Clarification of outlook (guidance) 2024
Clarification of outlook (guidance) 2024
To Nasdaq OMX Copenhagen A/S
Company announcement no. 567
January 15th, 2025
CLARIFICATION AND UPDATE ON FULL YEAR EXPECTATIONS FOR 2024
During Glunz & Jensen’s closing of the 2024 accounts and in preparation for the upcoming auditing of the 2024 figures, there are 2 minor deviations compared to the full year estimate which was approved by the board of directors in August 2024 and announced to the market:
- Two partially prepaid units (equipment) equal to approximately DKK 4 million in revenue were ready to be shipped during December 2024, but delivery has been postponed to 2025.
- The last quarter of 2024 (Q4, 2024) has shown strong profit margins, and furthermore Glunz & Jensen has managed to reduce the fixed cost even further.
Glunz & Jensen hereby wishes to clarify the full year 2024 expectations as follows:
- The revenue is expected at approximately DKK 131 million (previous outlook: approximately DKK 135 million)
- The EBITDA* is expected at approximately DKK 11 million (previous outlook: approximately DKK 12 million)
- The Profit before tax* is expected at approximately DKK 5 million (previous outlook: approximately DKK 5 million)
*The outlook on EBITDA and on Profit before tax is announced excluding potential adjustments on the fair value on the investment property.
Glunz & Jensen plans to announce its annual report for 2024 on March 19th, 2025.
For further information please contact:
CEO Henrik Blegvad Funk: phone +45 21 39 05 32
Chairman of the board Flemming Nyenstad Enevoldsen: phone +45 40 43 13 03
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Bombardier Inc.13.10.2025 22:02:56 CEST | Press release
Bombardier Global 8000, The World’s Fastest Business Jet, Gets Even Faster with a New Top Speed of Mach 0.95
Zymeworks Inc.13.10.2025 22:00:00 CEST | Press release
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Bombardier Inc.13.10.2025 21:00:00 CEST | Press release
Bombardier Unveils Comlux as Global 8000 Aircraft Customer, Delivery Confirmed for 2026
Cosmos Health Inc.13.10.2025 20:05:46 CEST | Press release
Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million
Sequana Medical NV13.10.2025 18:00:00 CEST | Press release
Press release: Transparency Notification from Shareholder
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom